Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

504.75 +5.01 (+1.00%)
Delayed Quote Updated: 1:28 PM EDT, Oct 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
77 78 Next >
News headline image
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
1 Reason I'll Never Sell Vertex Pharmaceuticals Stock ↗
The stock has climbed in the double-digits in recent years. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Which S&P500 stocks are moving on Wednesday? ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday. 
Via Chartmill
News headline image
Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today
Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 6.2% in the afternoon session after Morgan Stanley upgraded its rating on the stock to "Overweight" from "Equal-Weight" and... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
What's going on in today's session: S&P500 movers ↗
Stay updated with the movements of the S&P500 index in the middle of the day on Wednesday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
News headline image
2 Brilliant Growth Stocks to Buy Now and Hold for the Long Term ↗
Both can help drive excellent returns for patient, disciplined investors. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
3 Top Stocks to Buy in December ↗
These stocks deserve a spot on investors' shopping lists this holiday season. 
Via The Motley Fool
News headline image
Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50% ↗
This company's first product has started to generate revenue. 
Via The Motley Fool
Topics ETFs
News headline image
Vertex (VRTX) Q3 2025 Earnings Call Transcript ↗
Vertex (VRTX) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Where Will Vertex Pharmaceuticals Be in 5 Years ↗
Prediction: Vertex will be much larger by the end of the decade. 
Via The Motley Fool
News headline image
2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon ↗
If you're investing for the next 30 years, don't overlook these top stocks. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why
Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 2.7% in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. 
Via StockStory
Topics Artificial Intelligence Economy Supply Chain
News headline image
2 Inflation-Proof Growth Stocks That Could Outperform the Market ↗
Inflation should have a minimal impact on these companies' financial results. And they also boast excellent growth prospects. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Presents a Compelling Case for Value Investors ↗
Vertex Pharmaceuticals (VRTX) presents a strong value investment case with a low P/E ratio, robust profitability, a healthy debt-free balance sheet, and accelerating earnings growth. 
Via Chartmill
News headline image
Agios Pharmaceuticals Plunges Over 50% as Sickle Cell Drug Delivers Mixed Phase 3 Results
Boston, MA – November 19, 2025 – Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) experienced a dramatic and immediate market backlash, with its stock plummeting over 51.00% following the announcement of... 
Via MarketMinute
News headline image
Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Here's How Much $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
1 Cash-Heavy Stock with Solid Fundamentals and 2 We Ignore
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,... 
Via StockStory
News headline image
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗
These stocks both have advanced in the double-digits in recent months. 
Via The Motley Fool
News headline image
Is Vertex Pharmaceuticals Inc Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
1 Incredible Reason to Buy Vertex Pharmaceuticals Stock in November ↗
It's a good idea to go against the current market sentiment on this one. 
Via The Motley Fool
News headline image
The Tech Tsunami: How Breakthroughs in AI, Quantum, and Green Energy Are Reshaping the Stock Market
The global financial markets are in the midst of a profound transformation, driven by an accelerating wave of technological advancements. From the intricate algorithms of Artificial Intelligence to the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
1 Safe-and-Steady Stock with Competitive Advantages and 2 We Brush Off
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Top Affordable Growth Stock ↗
Vertex Pharmaceuticals offers strong growth, solid profits, and a healthy balance sheet, all at a reasonable valuation compared to its biotech peers. 
Via Chartmill
News headline image
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call
Vertex Pharmaceuticals’ third quarter was marked by steady double-digit revenue growth, yet the market responded negatively as margin compression and operational investments weighed on sentiment.... 
Via StockStory
Topics Earnings
News headline image
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Global Markets Brace for Inflation's Enduring Grip: A November 2025 Outlook
As November 2025 unfolds, global financial markets find themselves in a complex and challenging environment, bracing for the enduring grip of inflation. Despite some signs of moderating headline... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
77 78 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.